Data gathered: November 25
AI Stock Analysis - Humacyte (HUMA)
Analysis generated November 10, 2024. Powered by Chat GPT.
Humacyte is a pioneering biotechnology company focused on the development of bioengineered human tissue. Utilizing their proprietary technology platform, Humacyte addresses serious unmet medical needs with a range of potential applications, spanning vascular and non-vascular markets.
Stock Alerts - Humacyte (HUMA)
 |
Humacyte | November 25 Price is down by -5.4% in the last 24h. |
|
Humacyte | November 22 Insider Alert: Niklason Laura E is buying shares |
|
Humacyte | November 21 Insider Alert: Niklason Laura E is selling shares |
|
Humacyte | November 19 Price is down by -5.3% in the last 24h. |
Alternative Data for Humacyte
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 6 | Sign up | Sign up | Sign up |
| Sentiment | 95 | Sign up | Sign up | Sign up |
| Webpage traffic | 28,000 | Sign up | Sign up | Sign up |
| Employee Rating | 72 | Sign up | Sign up | Sign up |
| Google Trends | 4 | Sign up | Sign up | Sign up |
| Patents | 1 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 16 | Sign up | Sign up | Sign up |
| Facebook Followers | 169 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 15 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 5,780 | Sign up | Sign up | Sign up |
| Twitter Followers | 1,758 | Sign up | Sign up | Sign up |
| Twitter Mentions | 14 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 392 | Sign up | Sign up | Sign up |
| News Mentions | 1 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 62 | Sign up | Sign up | Sign up |
| Linkedin Employees | 220 | Sign up | Sign up | Sign up |
About Humacyte
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas.
| Price | $4.28 |
| Target Price | Sign up |
| Volume | 2,840,000 |
| Market Cap | $578M |
| Year Range | $2.87 - $9.46 |
| Dividend Yield | 0% |
| Analyst Rating | 83% buy |
| Industry | Biotechnology |
In the news
Humacyte (HUMA) Faces Class Action Lawsuit After FDA Inspection Reveals Manufacturing Issues – Hagens BermanNovember 25 - GlobeNewswire |
|
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HUMANovember 24 - GlobeNewswire |
|
Humacyte, Inc. Shareholder Alert: Robbins LLP Reminds Investors of the HUMA Securities Class ActionNovember 23 - GlobeNewswire |
|
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HUMANovember 22 - Finnhub |
|
Humacyte to Present Efficacy and Safety Results from V007 Phase 3 AV Access Clinical Trial at the 51st Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITH)November 22 - GlobeNewswire |
|
HUMA Bronstein, Gewirtz & Grossman LLC Announces that Humacyte, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitNovember 22 - Finnhub |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 0 | 7.3M | -7.3M | -39M | -30M | 0.000 |
| Q2 '24 | 0 | 5.7M | -5.7M | -57M | -29M | -0.480 |
| Q1 '24 | 0 | 5.8M | -7.6M | -32M | -30M | -0.290 |
| Q4 '23 | 11M | 6.5M | -8.3M | -25M | -23M | -0.240 |
| Q3 '23 | 0 | 6.1M | -7.5M | -26M | -24M | -0.250 |
Insider Transactions View All
| Dougan Brady W filed to sell 1,730,884 shares at $4.4. November 20 '24 |
| Niklason Laura E filed to sell 1,730,884 shares at $4.4. November 20 '24 |
| Dougan Brady W filed to buy 243,851 shares at $4.4. November 21 '24 |
| Niklason Laura E filed to buy 243,851 shares at $4.4. November 21 '24 |
| Dougan Brady W filed to sell 1,992,253 shares at $4.3. November 20 '24 |
Similar companies
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Thomas Tuberville Republican |
May 15, 24 | Sell | $50K - $100K |
| Thomas Tuberville Republican |
Apr 15, 24 | Buy | $1K - $15K |
| Thomas Tuberville Republican |
Apr 15, 24 | Buy | $1K - $15K |
Read more about Humacyte (HUMA) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Humacyte?
The Market Cap of Humacyte is $578M.
What is the current stock price of Humacyte?
Currently, the price of one share of Humacyte stock is $4.28.
How can I analyze the HUMA stock price chart for investment decisions?
The HUMA stock price chart above provides a comprehensive visual representation of Humacyte's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Humacyte shares. Our platform offers an up-to-date HUMA stock price chart, along with technical data analysis and alternative data insights.
Does HUMA offer dividends to its shareholders?
As of our latest update, Humacyte (HUMA) does not offer dividends to its shareholders. Investors interested in Humacyte should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Humacyte?
Some of the similar stocks of Humacyte are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.